Pharmaceutical regulatory authorities and industry leaders have long been challenged with reconciling their industry’s innovative driving force with its heavy controls and regulations. They are faced with maintaining a delicate balance of benefit vs risk– and with the daunting challenge of achieving this balance at an industry-level scale.
This duality is perhaps most acute in the area of pharmacovigilance (PV), where the people, processes, and technology involved are key parts of the most critical aspects of the product lifecycle. The nature of PV requires a conservative approach and operation, and so often follows the technology and systems that support it. However, this conservativism can create barriers to innovation or new efficiencies.
In this whitepaper, learn how the right combination of out-of-the-box Pharmacovigilance (PV) features and technology platform capabilities can help both industry and regulators “future-proof” their PV operations.